← Search stocks

Eli Lilly and (LLY)

Symbol

LLY

Sector

Healthcare

Industry

Drug Manufacturers - General

Instrument type

EQUITY

Profile information from the app’s catalog. This is not a live quote or confirmation of current listing status.

Related research

Eli Lilly’s ($LLY) olomorasib received FDA Breakthrough Therapy designation for treating advanced KRAS G12C-mutated pancreatic cancer.
Sep 29, 2026

Eli Lilly’s shares reached a new all time high following strong business developments and UK approval of Foundayo.
Aug 22, 2026

The UK approved Eli Lilly’s orforglipron, marketed as Foundayo, on August 10, 2026.
Aug 10, 2026

JPMorgan raised its price target on Eli Lilly (LLY) from $1,300 to $1,400, maintaining an Overweight rating and calling it its top healthcare pick.
Jul 9, 2026

Visa is building AI payment infrastructure, aiming to become the trusted backbone for AI agents that can autonomously research and purchase products online.
Jul 9, 2026

U.S. healthcare spending reached $5.7 trillion in 2025, up 7.3% year-over-year, driven by an aging population and rising demand.
Jul 7, 2026

Eli Lilly expanded its R&D pipeline by entering a new research collaboration with Abbisko, reinforcing its strategy of partnering externally to develop future therapies.
Jul 7, 2026

Eli Lilly surged +4% after raising its full-year revenue and profit forecast, driven by strong demand for weight-loss and diabetes drugs.
May 1, 2026

Eli Lilly (LLY) agreed to acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion.
Apr 20, 2026